Evidence map›Paper›PMID 28031707›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease2017

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.

Peter M Calverley, Göran Eriksson, Christine R Jenkins, Antonio R Anzueto, Barry J Make, Anders Persson, Malin Fagerås, Dirkje S Postma

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Longitudinal FEVInternational journal of chronic obstructive pulmonary disease
    Trial
  4. Article
  5. Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?International journal of chronic obstructive pulmonary disease · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 5 countries.

Peter M CalverleyPulmonary and Rehabilitation Research Group, University Hospital Aintree, Liverpool, UK.
Göran ErikssonDepartment of Respiratory Medicine and Allergology, University Hospital, Lund, Sweden.
Christine R JenkinsGeorge Institute for Global Health, The University of Sydney and Concord Clinical School, Sydney, Australia.
Antonio R AnzuetoDepartment of Pulmonary Medicine and Allergology, University of Texas Health Sciences Center and South Texas Veterans' Health Care System, San Antonio, Texas.
Barry J MakeDivision of Pulmonary Sciences and Critical Care Medicine, National Jewish Health, University of Colorado, Denver, Colorado, USA.
Anders PerssonAstraZeneca R&D, Gothenburg, Sweden.
Malin FageråsAstraZeneca R&D, Gothenburg, Sweden.
Dirkje S PostmaDepartment of Pulmonary Medicine and Tuberculosis, GRIAC Research Institute, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
AstraZeneca (Sweden) · SEAintree University Hospital · GBLund University · SENational Jewish Health · USSouth Texas Veterans Health Care System · USThe George Institute for Global Health · AUUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveLarge clinical trials have confirmed the long-term efficacy of inhaled corticosteroid/long-acting β

methodsPost hoc analysis of 3-month post-randomization outcomes, including exacerbation rates, dropouts, symptoms, reliever use, and lung function, from three studies with similar inclusion criteria of moderate-to-very-severe COPD. Patients (n=1,571) were treated with budesonide/formoterol (B/F) 320/9 μg or placebo, twice daily; in one study, tiotropium 18 μg once daily was also given.

resultsOver the first 3 months of treatment, fewer patients randomized to B/F experienced exacerbations versus the placebo group (111 and 196 patients with ≥1 exacerbation, respectively). This was true in each COPD severity group. Compared with placebo, B/F treatment led to significantly lower 3-month exacerbation rates in the moderate and severe COPD severity groups (46% and 57% reduction, respectively), with a nonsignificant reduction (29%) in very severe COPD. Fewer dropouts occurred among patients treated with B/F versus placebo, this effect being greater with increasing COPD severity. B/F was associated with improved forced expiratory volume in 1 s, morning peak expiratory flow rate, total reliever use, and total symptom score versus placebo.

conclusionTreatment with B/F decreased exacerbations in patients with moderate-to-very-severe COPD within 3 months of commencing treatment. This effect was paralleled by improved lung function, less reliever medication use, and fewer symptoms, irrespective of disease severity.

Indexed as

Administration, InhalationAdrenergic beta-2 Receptor AgonistsAgedBronchodilator AgentsBudesonide, Formoterol Fumarate Drug CombinationDisease ProgressionFemaleForced Expiratory VolumeGlucocorticoidsHumansLungMaleMiddle AgedPatient DropoutsPulmonary Disease, Chronic ObstructiveRecovery of FunctionAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsBudesonide, Formoterol Fumarate Drug CombinationGlucocorticoidsbronchodilator agentsclinical respiratory medicineclinical trialsCOPD

Identifiers

PMID28031707
PMCPMC5182036
OpenAlexW2565417974

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.